CORDIS
EU research results

CORDIS

English EN

Exploiting the pathophysiology of the gut towards innovative oral peptide delivery strategies

Project information

Grant agreement ID: 850997

Status

Ongoing project

  • Start date

    1 January 2020

  • End date

    31 December 2024

Funded under:

H2020-EU.1.1.

  • Overall budget:

    € 1 488 937,50

  • EU contribution

    € 1 488 937,50

Hosted by:

UNIVERSITE CATHOLIQUE DE LOUVAIN

Belgium

Project description

English EN

Bioactive nanocarriers as an oral peptide delivery strategy

Development of a novel oral drug delivery system for therapeutic peptides is a major challenge in the treatment of chronic diseases such as type 2 diabetes. This EU-funded project will work on the application of nanocarriers for peptide delivery, which protects its cargo against chemical and enzymatic degradation while enabling controlled release, targeting and increased bio-availability. Project strategy stems from an earlier observation that lipid-based nanocarriers themselves trigger endogenous bio-active peptide secretion in vivo after oral administration to mice. Current research will aim to develop a dual-action delivery system that combines the biological effect of the nanocarriers and that of the encapsulated drug to enable complex and very efficient treatments for gastrointestinal disorders.

Host institution

UNIVERSITE CATHOLIQUE DE LOUVAIN

Address

Place De L Universite 1
1348 Louvain La Neuve

Belgium

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 1 488 937,50

Beneficiaries (1)

UNIVERSITE CATHOLIQUE DE LOUVAIN

Belgium

EU Contribution

€ 1 488 937,50

Project information

Grant agreement ID: 850997

Status

Ongoing project

  • Start date

    1 January 2020

  • End date

    31 December 2024

Funded under:

H2020-EU.1.1.

  • Overall budget:

    € 1 488 937,50

  • EU contribution

    € 1 488 937,50

Hosted by:

UNIVERSITE CATHOLIQUE DE LOUVAIN

Belgium